Your Source for Venture Capital and Private Equity Financings

VC-funded Company:

Black Diamond Therapeutics
139 Main Street, Suite 301
Cambridge, MA 02142

Black Diamond Therapeutics is a precision oncology medicine company pioneering the discovery of small molecule, tumor-agnostic therapies. Black Diamond targets undrugged mutations in patients with genetically defined cancers. Black Diamond is built upon a deep understanding of cancer genetics, protein structure and function, and medicinal chemistry. The Company's proprietary technology platform, Mutation-Allostery-Pharmacology, or MAP, platform, is designed to allow Black Diamond to analyze population-level genetic sequencing data to identify oncogenic mutations that promote cancer across tumor types, group these mutations into families, and develop a single small molecule therapy in a tumor-agnostic manner that targets a specific family of mutations.

Key Contact
Name
David M. Epstein
Title
President & CEO
E-Mail
Funding Events

Date
Amount
Type
Investors
Valuation
12/05/19 $85,000,000 Series C Boxer Capital
BVF Partners
Casdin Capital
Deerfield Management Company, L.P.
Invus
Janus Henderson Investors
Logos Capital
New Enterprise Associates
Nextech Invest
RA Capital Management
Versant Ventures
Wellington Management Company
undisclosed